Related Experiment Videos
Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
R Misiani1, P Bellavita, D Fenili
1Division of Nephrology and Dialysis, Ospedali Riuniti di Bergamo, Italy.
Insights
Interferon alfa-2a treatment for hepatitis C virus-associated cryoglobulinemia effectively reduces viral load and improves symptoms. However, cryoglobulinemia often returns after treatment cessation, indicating a close link between viral activity and disease manifestation.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Essential mixed cryoglobulinemia is often linked to hepatitis C virus (HCV) infection.
- The impact of interferon's antiviral activity on cryoglobulinemia manifestations is not well understood.
Purpose of the Study:
- To investigate the efficacy of interferon alfa-2a in treating HCV-associated type II cryoglobulinemia.
- To determine if the antiviral action of interferon influences clinical and biochemical disease markers.
Main Methods:
- A prospective randomized controlled trial involving 53 patients with HCV-associated type II cryoglobulinemia.
- Treatment group received recombinant interferon alfa-2a for 24 weeks; control group received standard care.
- Patients were monitored for 24-48 weeks post-treatment.
Main Results:
- HCV RNA became undetectable in 15/25 interferon-treated patients versus none in controls.
- Undetectable HCV RNA correlated with significant improvements in vasculitis, cryoglobulins, and inflammatory markers.
- Viremia and cryoglobulinemia recurred in all patients after interferon discontinuation, with partial response upon re-treatment.
Conclusions:
- Therapeutic efficacy of interferon alfa-2a is directly related to its antiviral activity in HCV-associated cryoglobulinemia.
- Findings support the hypothesis that HCV infection is a causative factor in this condition.
Background:
Essential mixed cryoglobulinemia is frequently associated with hepatitis C virus (HCV) infection. A beneficial effect of interferon alfa therapy has been reported, but we do not know whether the antiviral activity of the drug affects the clinical and biochemical manifestations of disease.
Methods:
In a prospective randomized, controlled trial, we studied 53 patients with HCV-associated type II cryoglobulinemia. A group of 27 patients received recombinant interferon alfa-2a thrice weekly at a dose of 1.5 million units for a week and then 3 million units thrice weekly for the following 23 weeks. The 26 control patients did not receive anything apart from previously prescribed treatments. All patients were then followed for an additional 24 to 48 weeks.
Results:
Interferon was usually well tolerated, but it was permanently discontinued in two patients because of atrial fibrillation and depression. Two of the 26 patients in the control group were lost to follow-up. After the treatment period, serum HCV RNA was undetectable in 15 of the remaining 25 patients who received interferon alfa-2a, but in none of the controls. In comparison with the control group, the 15 patients with undetectable levels of HCV RNA in serum had significant improvement in cutaneous vasculitis (P = 0.04) and significant decreases in serum levels of anti-HCV-antibody activity (P = 0.007), cryoglobulins (P = 0.002), IgM (P = 0.002), rheumatoid factor (P = 0.001), and creatinine (P = 0.006). After treatment with interferon alfa-2a was discontinued, viremia and cryoglobulinemia recurred in all 15 HCV RNA-negative patients. On resumption of treatment, three of four patients had a virologic, clinical, and biochemical response.
Conclusions:
The therapeutic efficacy of interferon alfa-2a in HCV-associated cryoglobulinemia is closely related to its antiviral activity, thus supporting the idea that HCV infection may be a cause of this disease.